Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 held in Orlando, ...

"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "We ...

RIPPLE™ (Remote Induction of Pulsed Pressure Lateral to Energy) is a proprietary ultrasound-mediated delivery ...

Objective To determine how distinct combinations of resistance training prescription (RTx) variables (load, sets and frequency) affect muscle strength and hypertrophy. Data sources MEDLINE, Embase, ...

RIPPLE(TM) (Remote Induction of Pulsed Pressure Lateral to Energy) is a proprietary ultrasound-mediated delivery technology. -- RIPPLE(TM) has been developed to enable efficient, redosable, targeted, ...